Gilead Sciences Inc. (GILD)

65.23
0.12 0.18
NASDAQ : Health Technology
Prev Close 65.35
Open 65.30
Day Low/High 64.78 / 65.69
52 Wk Low/High 60.32 / 76.29
Volume 4.68M
Avg Volume 5.96M
Exchange NASDAQ
Shares Outstanding 1.27B
Market Cap 82.70B
EPS 4.20
P/E Ratio 9.16
Div & Yield 2.52 (3.81%)

Latest News

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

One Prescription for Uncertain Market? Gilead Sciences

One Prescription for Uncertain Market? Gilead Sciences

Use buy-write orders as a conservative way to invest in GILD in these uneasy times.

I'm Looking at Gilead and Merck for Buy Entry Positions

I'm Looking at Gilead and Merck for Buy Entry Positions

Let's see if either of these names provide an entry this week.

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

3 Autopilot Funds for a High-Yield Portfolio

3 Autopilot Funds for a High-Yield Portfolio

This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Gilead Sciences Is Regaining Its Shine

Gilead Sciences Is Regaining Its Shine

Revenue is stabilizing with new treatment lines, and this stock may be a soon be a buy.

Are These Stocks the Best of the Best?

Are These Stocks the Best of the Best?

Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.

Seattle Genetics Struggles as Other Biotech Stocks Rise

Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...

Inverted Yield Curve Has Lost a Lot of Its Predictive Power

The market has given up some of its early gains, but the major indices are all still in the black. Homebuilders have given up their 1% rally early today and now are flat. The Atlanta Fed's GDPNow has the economy growing 1.7% now from the last readin...

Before the Open

Less than a hour to go before the market open as we await the last trading day of the first quarter. Pre-market futures are still pointing to a up opening. Gilead Sciences is up some 2% this morning after developmental partner Galapagos announced so...

The Real Money Post Industrial Average Continues to Soar

The Real Money Post Industrial Average Continues to Soar

The RMPIA rose 10.5% during the first half of the current quarter.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

An Interesting Week For Dividends

An Interesting Week For Dividends

It's behavioral finance at its finest, and makes for a fascinating debate.

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Medicine is a slow business and I view Gilead Sciences as a hold for now.

What the Super Bowl Can Teach Us About Our Portfolio: Market Recon

What the Super Bowl Can Teach Us About Our Portfolio: Market Recon

And why maintaining a small position in defense stocks is important.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

3 Profitable Small Biotech Names to Consider

3 Profitable Small Biotech Names to Consider

Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

Gilead Sciences Is Sporting a Bearish Set of Charts for Investors

Gilead Sciences Is Sporting a Bearish Set of Charts for Investors

Gilead has been trying to turn things around but few see that turn coming anytime soon.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Be Ready to Ride the Dividend on Gilead Sciences

Be Ready to Ride the Dividend on Gilead Sciences

There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...